We used a panel of nine HER2+ breast cancer cell lines and evaluated their sensitivity to the FDA-approved HER2 kinase inhibitor lapatinib under conditions of monoculture (cancer cells only) or exposure to fibroblast-conditioned medium. This evidence concerns the gene ERBB2 and breast carcinoma.